ResTORbio Takes Immunotherapy Approach To Reducing Respiratory Tract Infections
Repurposing a TORC1 inhibitor investigated in several cancer types at Novartis, resTORbio has initiated a second Phase III study of RTB101 to address immunosenescence in older adults. CMO Joan Mannick discusses R&D strategy in interview at IDWeek.
You may also be interested in...
ResTORbio Pins Hopes On Parkinson’s After Failed CSRI Study
Company terminates studies of its TORC1 blocker after it fails to prevent respiratory illness in elderly patients with clinically symptomatic respiratory illness (CSRI). ResTORbio is hoping the same drug will be effective in Parkinson’s disease.
resTORbio's Age-Related RTI Program Picks Up Further Funding
Clinical studies by resTORbio into age-related immunosenescence attracts investors keen to advance a potential new class of immunotherapy agents.
PureTech Health: Applying Deep Thinking And Business Acumen
Targeting the age-dependent decline in immune function is the aim of a new PureTech Health subsidiary, resTORbio, that has licensed two clinical-stage mTORC1 inhibitors from Novartis.